Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
NEW YORK, August 4, 2016 /PRNewswire/ --
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
New York headquartered Synergy Pharmaceuticals Inc.'s shares gained 2.19%, closing Wednesday's trading session at $4.20. The stock recorded a trading volume of 1.38 million shares. Shares of the Company have advanced 9.95% in the last month and 44.83% in the previous three months. The stock is trading 9.82% above its 50-day moving average. Additionally, shares of Synergy Pharmaceuticals, which focuses on the development of drugs to treat gastrointestinal disorders and diseases, have a Relative Strength Index (RSI) of 61.12.
On July 15th, 2016, Synergy Pharmaceuticals announced that it has reached the FDA's mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). Furthermore, the company has decided to continue patient enrollment for its two ongoing phase 3 clinical trials with plecanatide in IBS-C. The decision to continue enrollment comes after trial monitoring demonstrated a slower enrollment pace combined with an increase in the number of patients not meeting randomization criteria after the screening period prior to starting treatment. SGYP complete research report is just a click away and free at:
On Wednesday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 2.48 million shares, which was above their three months average volume of 1.38 million shares. The stock fell 1.14%, ending the day at $55.35. The Company's shares have advanced 2.07% in the last month and 2.90% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.17% and 2.14%, respectively. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 47.40.
On August 2nd, 2016, Bloomberg reported that Novo Nordisk A/S's Victoza, a diabetes treatment that dominates its class of drugs, was shunned by U.S. pharmacy benefits manager Express Scripts Holding Co. for at least the second year in a row, signaling that the Danish company refused to concede on pricing. Victoza, the market leader among drugs known as GLP-1 analogs that stimulate insulin production, is forecasted to generate sales of $3.09 billion this year, according to analysts' estimates compiled by Bloomberg. The complimentary report on NVO can be downloaded at:
Danbury, Connecticut headquartered Biodel Inc.'s stock finished the day 5.00% lower at $0.40 and with a total volume of 324,914 shares traded. The Company's shares have gained 28.71% in the last one month, 7.84% in the previous three months, and 17.35% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 16.33% and 19.60%, respectively. Additionally, shares of Biodel, which focuses on the development and commercialization of treatments for diabetes in the United States, have an RSI of 59.05. Sign up for your complimentary research report on BIOD at:
Shares in Cupertino, California headquartered DURECT Corp. ended yesterday's session 2.17% higher at $1.88. The stock recorded a trading volume of 659,113 shares. The Company's shares have surged 57.98% in the last one month and 32.39% over the previous three months. The stock is trading 36.33% above its 50-day moving average and 21.48% above its 200-day moving average. Moreover, shares of DURECT, which researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms, have an RSI of 72.78.
On August 1st, 2016, DURECT announced that for the Q2 2016 total revenues were $3.2 million and net loss was for $9.0 million as compared to total revenues of $4.4 million and net loss of $5.5 million for the Q2 2015. As of June 30th, 2016, DURECT had cash and investments of $33.9 million compared to cash and investments of $29.3 million at December 31st, 2015. Get free access to your research report on DRRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA